圣达生物(603079) - 2018 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 10.23% to CNY 51,712,205.79 for the year-to-date period[5] - Operating revenue declined by 4.05% to CNY 354,627,576.65 for the year-to-date period[5] - Basic and diluted earnings per share decreased by 30.30% to CNY 0.46[6] - The weighted average return on net assets decreased by 4.99 percentage points to 6.59%[6] - Total revenue for Q3 2018 reached ¥140,232,266.78, an increase of 17.9% compared to ¥118,882,493.14 in Q3 2017[26] - Operating profit for Q3 2018 was ¥16,486,215.43, a decrease of 10.2% from ¥18,374,049.74 in the same period last year[27] - Net profit for Q3 2018 amounted to ¥14,355,811.91, down 10.1% from ¥15,962,182.14 in Q3 2017[27] - The total comprehensive income for the period was ¥14,355,811.91, compared to ¥15,962,182.14 in the same period last year, a decrease of about 10.06%[28] - The net profit for Q3 2018 was ¥9,402,591.65, down from ¥16,207,680.02 in Q3 2017, indicating a decrease of about 42.4%[30] - The basic and diluted earnings per share for Q3 2018 were both ¥0.13, compared to ¥0.17 in Q3 2017, reflecting a decline of approximately 23.53%[30] Assets and Liabilities - Total assets increased by 7.20% to CNY 1,056,963,960.05 compared to the end of the previous year[5] - The company's total assets reached CNY 1,056.96 million, up from CNY 985.98 million at the beginning of the year, indicating a growth of 7.19%[22] - The company's total liabilities increased to CNY 258.54 million from CNY 217.27 million, an increase of 19.06%[22] - The company's equity attributable to shareholders rose to CNY 798.42 million from CNY 768.71 million, reflecting a growth of 3.86%[22] - Total assets as of September 30, 2018, were ¥935,874,227.47, an increase from ¥889,347,841.34 at the beginning of the year[24] - Current liabilities increased to ¥163,693,638.32 from ¥148,801,077.91 at the beginning of the year, reflecting a rise of 10.5%[24] Cash Flow - Net cash flow from operating activities decreased by 44.69% to CNY 48,200,995.60 compared to the same period last year[5] - Cash flow from operating activities for the first nine months of 2018 was ¥404,584,173.74, compared to ¥381,060,246.04 in the same period last year, indicating an increase of about 6.2%[32] - The net cash flow from operating activities for the first nine months of 2018 was ¥41,815,669.53, a decrease of 37.3% compared to ¥66,573,800.60 in the same period last year[35] - Total cash inflow from operating activities was ¥271,922,881.20, up 3.4% from ¥261,616,928.47 year-on-year[35] - Cash outflow from investing activities resulted in a net cash flow of -¥28,725,422.60, slightly improved from -¥29,963,416.46 in the previous year[35] - Cash inflow from financing activities was ¥101,900,000.00, down from ¥369,800,000.00 in the same period last year[36] - The net cash flow from financing activities was ¥41,940,809.76, a decrease of 80.0% compared to ¥209,425,928.70 in the previous year[36] - The ending cash and cash equivalents balance was ¥232,883,505.20, down from ¥364,262,797.73 at the end of the previous year[36] Shareholder Information - The total number of shareholders at the end of the reporting period was 9,305[11] - The largest shareholder, Zhejiang Shengda Group, holds 28.94% of shares, with 7,980,000 shares pledged[11] Investment and Financing Activities - The company plans to raise CNY 136.34 million through the issuance of A-share convertible bonds for the acquisition and capital increase of Tongliao Huanghe Long Biotechnology Co., Ltd., with CNY 56.34 million allocated for acquiring 61.67% equity and CNY 80 million for capital increase[16] - The company has committed to using the funds raised from the convertible bond issuance to ensure the completion of the acquisition and capital increase, regardless of the approval status from the regulatory authority[17] Expenses - Sales expenses increased by 31.86% to CNY 11,621,227.00 mainly due to higher employee compensation and sales commissions[14] - The company reported a decrease in cash paid for dividends and interest, down 60.79% to CNY 24.35 million compared to CNY 62.11 million in the previous period[15] - Research and development expenses for Q3 2018 were ¥4,540,722.90, a decrease of 13.1% from ¥5,223,235.71 in Q3 2017[26] - The total operating costs for Q3 2018 were ¥124,642,545.39, an increase of 24.4% from ¥100,119,653.60 in Q3 2017[26] - The financial expenses for Q3 2018 showed a significant reduction, with a net financial income of -¥5,285,862.81 compared to ¥2,796,624.11 in Q3 2017, indicating improved financial management[30]